相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Infectious Diseases
Po Ying Chia et al.
Summary: This study found that mRNA vaccines are highly effective at preventing symptomatic and severe COVID-19 associated with B.1.617.2 infection. Vaccination is associated with a faster decline in viral RNA load and a robust serological response.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Editorial Material
Immunology
Simon D. Pollett et al.
Summary: This study characterizes 24 vaccine-breakthrough infections in mostly young healthy individuals, finding that while none required hospitalization, some experienced severe symptoms and shed high levels of live virus. The infecting genotypes included variant-of-concern (VOC) and non-VOC strains.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Jennifer M. Dan et al.
Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.
Article
Multidisciplinary Sciences
Sabari Nath Neerukonda et al.
Summary: Pseudoviruses are valuable surrogates for highly pathogenic viruses due to their safety, stability, and scalability, with diverse platforms offering varied advantages and limitations. This study optimized and characterized an HIV-based lentiviral pseudovirus assay for screening neutralizing antibodies for SARS-CoV-2, showing consistent neutralization titers across different input ranges and high correlation with other assays' results. Overall, the lentiviral assay is simple, scalable, and suitable for various SARS-CoV-2 entry and neutralization screening assays.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Infectious Diseases
Belinda M. Jackson-Thompson et al.
Summary: This study aims to determine the frequency of asymptomatic or pauci-symptomatic SARS-CoV-2 infection in at-risk healthcare workers, as well as the impact of antibodies to seasonal human coronaviruses on the course of COVID-19 disease. It will also evaluate the effects of pre-existing immune responses to seasonal HCoVs on the magnitude and duration of antibody and T cell responses to SARS-CoV-2 vaccination.
BMC INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Jackson S. Turner et al.
Summary: The study found that individuals who had recovered from mild SARS-CoV-2 infections showed rapid decline of serum anti-SARS-CoV-2 spike protein antibodies in the first 4 months after infection, followed by a more gradual decrease over the following 7 months but remaining detectable at least 11 months after infection. This suggests that mild infection with SARS-CoV-2 can induce robust antigen-specific, long-lived humoral immune memory in humans.
Article
Medicine, General & Internal
Mark G. Thompson et al.
Summary: The study demonstrated that COVID-19 mRNA vaccines were highly effective in preventing SARS-CoV-2 infection in real-world conditions, while also attenuating the viral RNA load, febrile symptoms, and illness duration among vaccinated individuals who had breakthrough infections.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Ashley Fowlkes et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
